國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Dendritic cell vaccination for relap...

Mount Sinai School of Medicine.

Dendritic cell vaccination for relapse after allogeneic transplantation .

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Dendritic cell vaccination for relapse after allogeneic transplantation .
作者:	Osman, Keren.
面頁冊數:	47 p.
附註:	Source: Masters Abstracts International, Volume: 49-05, page: 3134.
附註:	Adviser: Miriam Merad.
Contained By:	Masters Abstracts International49-05.
標題:	Health Sciences, Medicine and Surgery.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1491899
ISBN:	9781124619118

Dendritic cell vaccination for relapse after allogeneic transplantation .
Osman, Keren.

Dendritic cell vaccination for relapse after allogeneic transplantation . - 47 p.

Source: Masters Abstracts International, Volume: 49-05, page: 3134.

Thesis (M.S.)--Mount Sinai School of Medicine, 2011.

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for many patients with hematological malignancies. The success of allo-HCT is largely based on graft-versus-tumor effects. A fraction of patients who relapse after allo-HCT can be salvaged by donor lymphocyte infusion, thereby providing evidence of the importance of immune responses in cancer rejection. There is evidence that host dendritic cells (DCs) play a critical role in priming donor T cells to induce anti-tumor responses. We hypothesize that Vaccination of patients undergoing allo-HCT with ex vivo generated host DCs will enhance graft versus tumor responses and result in improved clinical outcomes.

ISBN: 9781124619118Subjects--Topical Terms:

212619
Health Sciences, Medicine and Surgery.

Dendritic cell vaccination for relapse after allogeneic transplantation .
LDR:01998nmm 2200313 4500 001 317508
005 20120109075424.5
008 120208s2011 ||||||||||||||||| ||eng d
020 $a 9781124619118
035 $a (UMI)AAI1491899
035 $a AAI1491899
040 $a UMI $c UMI
100 1 $a Osman, Keren. $3 542082
245 1 0 $a Dendritic cell vaccination for relapse after allogeneic transplantation .
300 $a 47 p.
500 $a Source: Masters Abstracts International, Volume: 49-05, page: 3134.
500 $a Adviser: Miriam Merad.
502 $a Thesis (M.S.)--Mount Sinai School of Medicine, 2011.
520 $a Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for many patients with hematological malignancies. The success of allo-HCT is largely based on graft-versus-tumor effects. A fraction of patients who relapse after allo-HCT can be salvaged by donor lymphocyte infusion, thereby providing evidence of the importance of immune responses in cancer rejection. There is evidence that host dendritic cells (DCs) play a critical role in priming donor T cells to induce anti-tumor responses. We hypothesize that Vaccination of patients undergoing allo-HCT with ex vivo generated host DCs will enhance graft versus tumor responses and result in improved clinical outcomes.
520 $a We propose a proof-of-concept clinical trial in which we will inject host DCs in patients allo-HCT to examine whether infusion of host DCs either alone or in addition to donor lymphocyte infusion safe in patients that relapse after allo-HCT; and ii) to assess generation of immune responses against host antigens.
590 $a School code: 1623.
650 4 $a Health Sciences, Medicine and Surgery. $3 212619
650 4 $a Health Sciences, Immunology. $3 226966
690 $a 0564
690 $a 0982
710 2 $a Mount Sinai School of Medicine. $b Biological Sciences. $3 542083
773 0 $t Masters Abstracts International $g 49-05.
790 1 0 $a Merad, Miriam, $e advisor
790 1 0 $a Gabrilove, Janice $e committee member
790 1 0 $a Moskowitz, Alan $e committee member
790 $a 1623
791 $a M.S.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1491899